📊 EWTX Key Takeaways
Is Edgewise Therapeutics, Inc. (EWTX) a Good Investment?
Edgewise Therapeutics is a pre-revenue biotech company with severe cash burn of $144M in free cash flow annually, eroding equity at a -30.4% ROA despite maintaining a strong cash position of $61M. The company faces existential risk with current burn rates allowing only 4-5 quarters of operations, and no revenue generation indicates clinical-stage or failed commercialization.
Edgewise Therapeutics shows very strong balance-sheet quality, with $522.26M of equity, minimal debt, and exceptional liquidity ratios that materially reduce near-term financing stress. However, the business remains pre-revenue and deeply unprofitable, with $167.79M in net losses and negative free cash flow of $144.07M, so the fundamental case depends on future clinical and commercialization execution rather than current operating performance.
Why Buy Edgewise Therapeutics, Inc. Stock? EWTX Key Strengths
- Strong balance sheet with $522.3M stockholders equity and minimal debt ($59K)
- Excellent liquidity with 19.85x current ratio providing near-term operational cushion
- Low leverage profile with 0.00x debt-to-equity ratio reducing financial distress risk
- Very strong liquidity with 19.85x current and quick ratios
- Low financial leverage with essentially no long-term debt
- Large equity base and cash resources support ongoing R&D investment
EWTX Stock Risks: Edgewise Therapeutics, Inc. Investment Risks
- Massive annual cash burn of $144.1M with only ~4-5 quarters of cash runway remaining
- Zero revenue generation indicating failed product commercialization or early-stage development
- Deteriorating financial performance with negative ROE of -32.1% and ROA of -30.4%, destroying shareholder value
- Operating losses of $191.4M annually unsustainable without successful product launch or funding
- No revenue base, making growth quality and operating leverage unproven
- Large recurring losses and cash burn could require future capital raises if development timelines slip
- Negative returns on assets and equity indicate weak current capital efficiency
Key Metrics to Watch
- Operating cash burn rate and cash runway months remaining
- Clinical trial progress and FDA approval milestones for pipeline drugs
- Revenue recognition from any approved or launched pharmaceutical products
- Equity dilution from potential secondary offerings or financing activities
- Quarterly operating cash burn and ending cash balance
- Revenue emergence or clinical milestones that improve commercialization visibility
Edgewise Therapeutics, Inc. (EWTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 19.85x current ratio provides a solid financial cushion.
EWTX Profit Margin, ROE & Profitability Analysis
EWTX vs Healthcare Sector: How Edgewise Therapeutics, Inc. Compares
How Edgewise Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Edgewise Therapeutics, Inc. Stock Overvalued? EWTX Valuation Analysis 2026
Based on fundamental analysis, Edgewise Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Edgewise Therapeutics, Inc. Balance Sheet: EWTX Debt, Cash & Liquidity
EWTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Edgewise Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.57 indicates the company is currently unprofitable.
EWTX Revenue Growth, EPS Growth & YoY Performance
Edgewise Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
EWTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Edgewise Therapeutics, Inc. (CIK: 0001710072)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EWTX
What is the AI rating for EWTX?
Edgewise Therapeutics, Inc. (EWTX) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (HOLD) with 83% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are EWTX's key strengths?
Claude: Strong balance sheet with $522.3M stockholders equity and minimal debt ($59K). Excellent liquidity with 19.85x current ratio providing near-term operational cushion. ChatGPT: Very strong liquidity with 19.85x current and quick ratios. Low financial leverage with essentially no long-term debt.
What are the risks of investing in EWTX?
Claude: Massive annual cash burn of $144.1M with only ~4-5 quarters of cash runway remaining. Zero revenue generation indicating failed product commercialization or early-stage development. ChatGPT: No revenue base, making growth quality and operating leverage unproven. Large recurring losses and cash burn could require future capital raises if development timelines slip.
What is EWTX's revenue and growth?
Edgewise Therapeutics, Inc. reported revenue of N/A.
Does EWTX pay dividends?
Edgewise Therapeutics, Inc. does not currently pay dividends.
Where can I find EWTX SEC filings?
Official SEC filings for Edgewise Therapeutics, Inc. (CIK: 0001710072) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EWTX's EPS?
Edgewise Therapeutics, Inc. has a diluted EPS of $-1.63.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EWTX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Edgewise Therapeutics, Inc. has a SELL rating with 83% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is EWTX stock overvalued or undervalued?
Valuation metrics for EWTX: ROE of -32.1% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy EWTX stock in 2026?
Our dual AI analysis gives Edgewise Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EWTX's free cash flow?
Edgewise Therapeutics, Inc.'s operating cash flow is $-143.8M, with capital expenditures of $256.0K.
How does EWTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -32.1% (avg: 15%), current ratio 19.85 (avg: 2).